You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Boehringer Ingelheim
McKinsey
Harvard Business School
Baxter

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,861,631

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,861,631 protect, and when does it expire?

Patent 9,861,631 protects MIRVASO and is included in one NDA.

This patent has eighty-one patent family members in twenty-four countries.

Summary for Patent: 9,861,631
Title:Methods and compositions for safe and effective treatment of erythema
Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.
Inventor(s): Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Hegenheim, FR), Freidenreich; Philip (Yardley, PA), Liu; Yin-sang (Princeton Junction, NJ), Leoni; Matthew James (Titusville, NJ)
Assignee: Galderma Laboratories, L.P. (Fort Worth, TX)
Application Number:14/679,598
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,861,631

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes   Start Trial   Start Trial TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,861,631

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 530185   Start Trial
Australia 2004242967   Start Trial
Australia 2005247467   Start Trial
Australia 2011231543   Start Trial
Brazil 112012024289   Start Trial
Brazil PI0511519   Start Trial
Canada 2530938   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Merck
Mallinckrodt
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.